Comparison
Abetaa21g Amyloidosis C3888307 vs 17q24 2 Microdeletion Syndrome C5680185
Clinical comparison between Abetaa21g Amyloidosis and 17q24 2 Microdeletion Syndrome for differential diagnosis and treatment planning.
Abetaa21g Amyloidosis C3888307
Hereditary cerebral amyloid angiopathy from APP gene mutation. Family-linked condition. Associated with brain hemorrhage risk.
17q24 2 Microdeletion Syndrome C5680185
A rare genetic disorder caused by deletion of genetic material on chromosome 17. Individuals may have developmental delays, facial features, and other medical issues. Care is supportive and multidisciplinary.
6 comparison axes
Onset
Abetaa21g Amyloidosis C3888307
40-60
17q24 2 Microdeletion Syndrome C5680185
0-null
Onset patterns differ
Severity
Abetaa21g Amyloidosis C3888307
severe
17q24 2 Microdeletion Syndrome C5680185
moderate
Different severity levels
Chronic
Abetaa21g Amyloidosis C3888307
Chronic
17q24 2 Microdeletion Syndrome C5680185
Chronic
Differing course
Communicable
Abetaa21g Amyloidosis C3888307
No
17q24 2 Microdeletion Syndrome C5680185
No
Different transmission
Body System
Abetaa21g Amyloidosis C3888307
neurologic
17q24 2 Microdeletion Syndrome C5680185
congenital
Same/different system
Category
Abetaa21g Amyloidosis C3888307
rare-disease
17q24 2 Microdeletion Syndrome C5680185
genetic
Different category
Bottom line
abetaa21g-amyloidosis-C3888307 and 17q24-2-microdeletion-syndrome-C5680185 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abetaa21g Amyloidosis C3888307 | 17q24 2 Microdeletion Syndrome C5680185 | Discriminating power |
|---|---|---|---|
| Age at recognition | Typically recognized in adulthood, often ages 40–60. | Present from birth or early childhood. | High |
| Neurologic presentation | Recurrent or lobar brain hemorrhage may occur; exact symptoms vary. | Developmental delay is described; stroke is not a defining feature. | High |
| Congenital features | No established congenital dysmorphic pattern in the supplied data. | Facial features and other medical issues may be present. | Moderate |
When to favor each condition
Choose Abetaa21g Amyloidosis C3888307 when
Adult with familial brain hemorrhage
Adult onset and APP-related hereditary cerebral amyloid angiopathy fit this pattern.
Moderate
Family history suggesting APP mutation
The condition is family-linked and attributed to an APP gene mutation.
Moderate
No congenital developmental syndrome
Absence of early congenital features makes the microdeletion less likely.
Low
Choose 17q24 2 Microdeletion Syndrome C5680185 when
Congenital developmental concerns
Early developmental delay supports evaluation for a chromosomal microdeletion.
Moderate
Dysmorphic or multisystem findings
Facial features and other medical issues are described for this syndrome.
Moderate
No adult hemorrhagic phenotype
Lack of familial adult brain hemorrhage argues against AβA21G amyloidosis.
Low
How key tests differ
| Test | Abetaa21g Amyloidosis C3888307 | 17q24 2 Microdeletion Syndrome C5680185 | Interpretation |
|---|---|---|---|
| APP genetic testing | May identify the disease-associated APP mutation when clinically indicated. | Not expected to explain a 17q24.2 deletion. | A positive result supports the amyloidosis; absence does not exclude all hereditary causes. |
| Chromosomal microarray | Not the primary test for an APP point mutation. | May detect a 17q24.2 microdeletion. | Array findings require laboratory and clinician correlation. |
| Brain imaging | May show hemorrhage or related changes, but findings are not specific. | No characteristic hemorrhagic pattern is established here. | Imaging cannot by itself establish either diagnosis. |
Prognosis comparison
Abetaa21g Amyloidosis C3888307
- Outcome
- Potentially severe because of brain-hemorrhage risk; individual outcome is not established here.
- Factors
- Age, hemorrhage history, and confirmed APP status may influence care, but exact effects are not supplied.
17q24 2 Microdeletion Syndrome C5680185
- Outcome
- Generally described as moderate, with variable developmental and medical needs.
- Factors
- Extent of deletion and associated medical issues may matter; precise predictors are not established.
Time frame: Left is adult-onset and chronic; right begins congenitally and is chronic.
Prognosis should be individualized by a clinician; no mortality or universal outcome is established.
Complications comparison
| Complication | Presentation |
|---|---|
| Brain hemorrhage | A recognized associated risk. Not established from the supplied description. Any suspected hemorrhage needs urgent clinical assessment. |
| Developmental disability | Not described as a congenital feature. Developmental delay may occur. Severity and functional impact vary and are not quantified here. |
| Multisystem medical needs | Primarily neurologic in the supplied data. Other medical issues may require coordinated care. Specific complications should not be assumed without evaluation. |
Patient education highlights
- HighDifferent conditions
These are distinct genetic conditions and one result does not diagnose the other.
- HighUrgent symptoms
Sudden neurologic symptoms require emergency care, especially when hemorrhage risk is known.
- MediumGenetic counseling
Families may benefit from counseling about inheritance, testing limits, and reproductive options.